


Ask a doctor about a prescription for EBASTINE FLAS STADA 10 mg ORALLY DISINTEGRATING TABLETS
Package Leaflet: Information for the Patient
Ebastine Flas Stada 10 mg Oral Dispersible Tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Ebastine is a medication used to treat allergies (antihistamine). It helps control the symptoms of an allergic reaction.
It is indicated in adults and children 12 years of age or older for the treatment of seasonal or perennial allergic rhinitis (hay fever) with or without allergic conjunctivitis (eye inflammation), and for the treatment of urticaria (hives) in adults over 18 years of age.
DO NOT take Ebastine Flas Stada
Warnings and Precautions
Consult your doctor or pharmacist before taking Ebastine Flas Stada:
Children and Adolescents
Taking Ebastine Flas Stada with other medications
Tell your doctor or pharmacist that you are taking, have recently taken, or may need to take any other medication.
Ebastine may affect or be affected by other medications that contain the following active ingredients:
Taking Ebastine Flas Stada with food and drinks
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Breastfeeding
Driving and Using Machines
Ebastine Flas Stada contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per oral dispersible tablet; this is, essentially "sodium-free".
Follow your doctor's instructions for taking this medication exactly. If you have any doubts, consult your doctor or pharmacist again.
The recommended dose is:
For the treatment of allergic rhinitis (hay fever) with or without allergic conjunctivitis (eye inflammation)
For adults and adolescents 12 years of age or older:
Urticaria (hives)
Adults 18 years of age or older:
Use in Children and Adolescents
Ebastine should not be used in children under 12 years of age.
Ebastine should not be used to treat urticaria (hives) in patients under 18 years of age.
Patients with Renal Impairment
Patients with renal impairment do not need to adjust the dose.
Patients with Severe Liver Impairment
The dose should not exceed 10 mg in these patients.
Patients with Mild to Moderate Liver Impairment
Patients with mild to moderate liver impairment do not need to adjust the dose.
Method of Administration
Duration of Treatment
Your doctor will decide the duration of treatment with ebastine.
If you take more Ebastine Flas Stada than you should
If you forget to take Ebastine Flas Stada
Do not take a double dose to make up for forgotten doses. Take the next dose at the usual time.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone gets them.
Very Common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 1,000 people)
Not Known (frequency cannot be estimated from available data)
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
This medication does not require special storage conditions.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the carton after EXP. The expiration date is the last day of the month indicated.
Medications should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medication in the SIGRE collection point at your pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Ebastine Flas Stada
*Composition: natural flavoring, identical natural flavoring, acacia gum (E-414), maltodextrin, sodium benzoate (E-211), butylated hydroxyanisole (E-320).
Appearance of the Product and Package Contents
Ebastine Flas Stada 10 mg are oral dispersible tablets, white to off-white, round, flat with beveled edges, approximately 8.50 mm in diameter and 2.20 mm in thickness, marked with "10" on one side and smooth on the other.
The oral dispersible tablets are packaged in peelable OPA/Alu/PVC - Paper/PET/Alu blisters. Ebastine Flas Stada 10 mg is available in cartons containing 20 and 30 oral dispersible tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
or
Meiji Pharma Spain, S.A.
Avda. de Madrid, 94
28802 Alcalá de Henares (Madrid)
Spain
This medication is authorized in the Member States of the European Economic Area under the following names:
Netherlands: NOTAXO 10 mg, orodispersible tablet
Italy: Ebastina EG 10 mg, orodispersible tablet
Spain: Ebastina Flas Stada 10 mg oral dispersible tablets EFG
Date of the last revision of this package leaflet:July 2019
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of EBASTINE FLAS STADA 10 mg ORALLY DISINTEGRATING TABLETS in November, 2025 is around 4.4 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for EBASTINE FLAS STADA 10 mg ORALLY DISINTEGRATING TABLETS – subject to medical assessment and local rules.